What Healsun Biopharm does

Healsun Biopharm (杭州皓阳生物技术有限公司) is a privately held, pure-play biopharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in November 2015 in Hangzhou, China. The company provides end-to-end services for antibody, bispecific antibody, fusion protein, and antibody-drug conjugate (ADC) drugs, spanning early-stage drugability assessment through commercial-scale GMP manufacturing. Its service portfolio is anchored by the proprietary HaoYue® stable cell line platform (CHO-K1 host cell based, with global sub-licensing rights) and a Fut8-knockout ADCC-enhanced variant, complemented by upstream/downstream process development, ADC conjugation (over 1,300 projects delivered), analytical testing (CNAS-accredited), formulation development, customized medium development, and gene therapy AAV/mRNA services. Manufacturing infrastructure spans three advanced production bases in Shanghai and Hangzhou totaling 52,500 m², with current GMP clinical lines (5,000 m² large molecule + 500 m² ADC) and a commercial-scale MFG2 facility (6×2,000 L antibody + 1×500 L ADC) under construction for end-2026 commissioning.

The company serves domestic and international biopharma companies developing innovative biologics and biosimilars, with over 150 customers served and 40+ IND-stage projects delivered to date. Notable clients include Beijing Lepu Pharmaceutical (China's first NMPA-approved dulaglutide biosimilar, full DNA-to-IND service), Ginkgo Pharma, Aikelian Bio, Fanli Bio, and Betta Pharma. Healsun is differentiated as a pure-play CDMO with no proprietary pipeline, eliminating competitive conflicts with clients. The company is fee-for-service, pricing projects on a per-project or milestone basis tied to molecule complexity and development stage. Go-to-market is B2B enterprise field sales with a dedicated BD team, supplemented by industry conferences, a technical thought-leadership platform (HaoQiXing/HaoXueBuJue), and an international market specialist targeting Europe and the US following the December 2024 EU QP audit pass.

The company has raised approximately USD 100M+ across multiple funding rounds: CNY 50M (2018 strategic), CNY 80M+ (A-round, April 2021, Yipu Capital + Haibang Investment), CNY ~250M (B-round, August 2022, led by Shanghai Biopharmaceutical Fund), undisclosed B+ round (October 2023), and a new equity round (November 2025). It has been recognized as a National High-Tech Enterprise, a 2022 Zhejiang Specialized and Sophisticated SME, and holds CNAS laboratory accreditation, ISO 9001:2015, and EU GMP QP certification. Headcount has grown from 4 founders to 220+ employees as of March 2023 across Hangzhou headquarters and a Shanghai R&D subsidiary opened in May 2023.

Name

Healsun Biopharm

Legal name

杭州皓阳生物技术有限公司

Website

https://hs-biopharm.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Healsun Biopharm is a Hangzhou-based pure-play biopharmaceutical CDMO providing end-to-end antibody, fusion protein, and ADC drug development and GMP manufacturing services for domestic and international biopharma companies, anchored by its proprietary HaoYue stable cell line platform.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

Keywords

• Biopharmaceutical CDMO services
• Antibody drug development
• Stable cell line platform
• ADC contract manufacturing
• GMP biologics manufacturing

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Service Fees (Full-Service Contract Development): Fee-for-service CDMO model covering the entire biologics development lifecycle: early drug developability assessment, stable cell line construction, process development (upstream/downstream/ADC), analytical method development, GMP clinical sample production, and commercial manufacturing. Revenue recognized as projects are executed and milestones are met. Core revenue stream for the pure-play biologics CDMO.
2. Media and Reagent Customization Services: Customized development and supply of cell culture media and feed for biologics manufacturing, including chemically defined培养基. Revenue from medium formulation customization services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Healsun Biopharm is a pure-play biopharmaceutical CDMO providing end-to-end contract development and manufacturing services for antibody, bispecific antibody, fusion protein, and ADC drugs. Services span early-stage drugability assessment, stable cell line construction (HaoYue platform), upstream/downstream process development, analytical testing, ADC conjugation, GMP clinical sample production, and commercial-scale manufacturing under FDA/EMA/NMPA cGMP standards.

Product overview

Healsun Biopharm is a pure-play biopharmaceutical CDMO offering end-to-end services for antibody, fusion protein, and ADC (antibody-drug conjugate) drugs from early-stage drugability assessment through commercial-scale GMP manufacturing. The company operates an integrated service portfolio anchored by the HaoYue® stable cell line platform (including the Fut8-KO ADCC-enhanced variant), complemented by upstream/downstream process development, ADC conjugation, analytical testing (CNAS/ISO 9001 certified), customized medium development, and formulation development services. The company maintains GMP clinical sample production lines for both large molecules (5,000 m²) and ADCs (500 m²), with commercial-scale manufacturing capacity under construction (6×2,000L). Services also include a gene therapy AAV/mRNA CRO platform and a catalog of research-grade tool proteins sold via an online shop.

Differentiator

Problem solved

Functional benefit

Products and services

• HaoYue® Stable Cell Line Platform (皓越) High-expression stable cell line development platform using commercially authorized CHO-K1 host cells combined with proprietary plasmid systems and cell line screening protocols. Delivers symmetric monoclonal/bispecific antibodies at ≥5 g/L (2024 average >6.8 g/L) within 10-12 weeks for biopharma clients developing antibody drugs.
• ADCC-Enhanced (Fut8-KO) Stable Cell Line Platform Fut8 knockout CHO-K1 cell line platform built on HaoYue®, enabling production of low-fucosylation antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. Fucose content stably below 1.5%.
• Host Cell Commercial Licensing (CHO-K1) Commercial licensing of CHO-K1 host cells for stable cell line development, with global sublicensing rights. Provided to biopharma clients building or expanding their own cell line development capabilities.
• Drugability Assessment Service (成药性评估) Early-stage systematic drugability assessment covering sequence analysis, ProA affinity purification, high-polymer detection (SEC-HPLC), hydrophobicity (HIC-HPLC), Tm value, MS-based PTM analysis, and pre-stability studies for candidate antibody and recombinant protein molecules.
• Upstream Process Development (上游工艺开发) QbD-based upstream process development using 16×3L and 4×15L bioreactors, ATF2 for perfusion/CFB, and 24 deep-well plates for high-throughput optimization. Supports glycosylation modulation and bispecific antibody fragment ratio control.
• Downstream Process Development (下游工艺开发) Antibody and recombinant protein purification process development using AKTA Pure/Avant, including chromatography, depth filtration, ultrafiltration, virus clearance (low pH, S/D, nanofiltration), and scale-down model process characterization. ~70% overall recovery within 8-12 weeks.
• Formulation Development (制剂处方工艺开发) Formulation development for monoclonal antibodies, bispecific antibodies, fusion proteins, and ADCs covering liquid and lyophilized dosage forms, including high-concentration formulation, stability studies, and packaging material compatibility per ICH and pharmacopeial standards.
• Customized Medium Development (培养基定制开发) Customized basal media, feed media, and perfusion media development for CHO cells using proprietary base formulation libraries; chemically defined, animal-free, no protein/peptides. Currently used in NMPA and FDA regulatory filings.
• ADC Platform (ADC药物平台) End-to-end antibody-drug conjugate services from early discovery through GMP manufacturing, including ADC drug screening, conjugation process development (random and site-specific), purification, analysis, and lyophilization. Over 1,300 conjugation projects delivered across 10+ small molecule linkers; GMP conjugation scale 20L-500L.
• GMP Clinical Sample Production — Large Molecule (临床样品生产-大分子) cGMP-compliant (FDA/EMA/NMPA) manufacturing of clinical-stage antibody drug substance and drug product on 5,000 m² lines producing 3,000g bulk drug substance per batch and 10,000 vials per filling batch. Antibody DNA to toxicology batch delivered in 7 months; Pre-IND package in 12 months.
• GMP Clinical Sample Production — ADC (ADC临床样品生产) Independent 500 m² ADC cGMP lines (FDA/EMA/NMPA) with OEB5-level negative pressure isolators and 50/100/150L single-use bioreactors. Annual capacity of 50 batches at 1,500g ADC per batch. Antibody DNA to ADC toxicology batch in 8 months; Pre-IND package in 13 months.
• Commercial Manufacturing — PC/PV (商业化生产) Process characterization (PC) and process validation (PV) services for commercial manufacturing readiness. Commercial lines under construction: 6×2,000L antibody bioreactors and 1×500L ADC conjugation line.
• Industrialization Service (产业化) Commercial-scale drug substance and drug product manufacturing: 6×2,000L antibody lines, 1×200L + 1×500L ADC lines, 100,000 vials/batch antibody vial line, 37,000 vials/batch antibody lyophilization line, 160,000 prefilled syringes/batch, 30,000 vials/batch ADC lyophilization line.
• Protein Engineering — Antibody Humanization (蛋白工程-人源化) Antibody humanization design reducing immunogenicity of murine monoclonals. Delivers humanization design, protein preparation, and affinity screening in 5 weeks with off-rate ranking within 3× of chimeric antibody.
• Yeast Cell Surface Display Service (酵母细胞表面展示) Yeast surface display technology for antibody sequence optimization including affinity maturation, cross-reactivity improvement, hydrophobicity improvement, and PTM site removal. 8 weeks from plasmid construction to protein delivery using HEK293/CHO transient expression.
• Analytical Support (理化/生化分析/蛋白表征) Comprehensive analytical services including SEC-HPLC, CE-SDS, icIEF, HIC-HPLC, HTRF, ELISA, cell-based potency, and LC-MS characterization. CNAS-accredited laboratory compliant with ISO 9001:2015.
• Tool Proteins (工具蛋白) Catalog of research-grade recombinant proteins modeled after marketed biologics (Trastuzumab, Bevacizumab, Pembrolizumab, Rituximab, etc.) available at gram and milligram scales. Sold via online shop at shop.hs-biopharm.com as research reagents and reference standards.
• Gene Therapy AAV/mRNA CRO Service (基因治疗) Full-process AAV/mRNA CRO services for gene therapy, including vector design, process development, and analytical support.

Quantifiable outcome

• ≥5g/L expression guarantee for symmetric mAb/bisAb stable cell lines; 2024 average exceeded 6.8g/L
• +8 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• Ginkgo Pharma (劲方医药)coreStrategic or Co-development Partner · 1 November 2025Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to post-marketing production services. Ginkgo Pharma is a clinical-stage biotech company developing innovative small molecule drugs.
• Aikelian Bio (艾科联生物)coreStrategic or Co-development Partner · 1 November 2025Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to上市后生产. Aikelian Bio is a biotech company developing innovative biologics.
• Fanli Bio (帆礼生物)coreStrategic or Co-development Partner · 1 November 2025Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to上市后生产. Fanli Bio is an innovative biologics company.
• Betta Pharma (贝达药业)coreStrategic or Co-development Partner · 1 November 2025Signed ecosystem strategic cooperation agreement at 10th anniversary ceremony (November 2025), leveraging 'dragon head + professional empowerment' model to activate industry innovation. Betta Pharma is a leading Chinese innovative pharmaceutical company listed on Shenzhen Stock Exchange (SZ:300558).

Scale indicators20 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Genscript ProBio: Genscript ProBio is the biologics CDMO arm of Genscript Biotech, providing cell line development, process development, and GMP manufacturing for antibodies, recombinant proteins, plasmids, and viral vectors. It is a direct peer to Healsun in cell line platforms and antibody CDMO services, with broader gene therapy capabilities.
• WuXi XDC: WuXi XDC is the dedicated ADC-focused CDMO spun out from WuXi Biologics, offering integrated discovery, development, and manufacturing services for antibody-drug conjugates. It is the most direct ADC-specific competitor to Healsun's 1,300+ conjugation project platform, with larger scale, established global clients, and broader payload/linker coverage.
• MabPlex International: MabPlex International is a Chinese biologics CDMO specializing in antibody and recombinant protein development and manufacturing, including ADC services. Closely comparable to Healsun as a mid-sized pure-play biologics CDMO with cell line development, process development, and GMP manufacturing for both antibodies and ADCs.
• WuXi Biologics: WuXi Biologics is China's largest and the world's leading open-access biologics CDMO, offering end-to-end services from cell line development to commercial manufacturing. It is the most direct competitor to Healsun, with overlapping antibody, bispecific, and ADC capabilities at significantly larger scale (over 10,000 employees, multiple global sites). Both companies target the same biopharma client base with fee-for-service biologics CDMO offerings.
• Porton Biologics: Porton Biologics is the biologics CDMO subsidiary of Porton Pharma, offering cell line construction, process development, and GMP manufacturing for monoclonal antibodies, bispecifics, fusion proteins, and ADCs. Closely comparable to Healsun as a Chinese biologics CDMO with end-to-end antibody and ADC services targeting similar customer segments.

Emerging players

• BiBo Biologics: BiBo Biologics (Shanghai) is an emerging Chinese biologics CDMO providing cell line development, process development, and GMP manufacturing services for antibodies and recombinant proteins. Comparable to Healsun as an emerging Chinese pure-play biologics CDMO targeting similar mid-sized biotech clients.
• DoBi Biologics: DoBi Biologics is an emerging Chinese CDMO with capabilities in cell line construction, process development, and GMP manufacturing for antibodies and recombinant proteins. Comparable to Healsun as a smaller emerging Chinese biologics CDMO serving similar early-to-mid-stage biotech clients.

Broad incumbents

• Pharmaron Biologics: Pharmaron is a global CRO/CDMO with integrated biologics capabilities as part of a broader service portfolio spanning small molecule, biologics, and gene therapy. Comparable to Healsun in biologics and ADC offerings, but operates as part of a much larger full-service platform with greater scale and geographic reach.
• Asymchem Laboratories: Asymchem is a leading Chinese CDMO historically focused on small-molecule APIs that has been expanding into biologics and oligonucleotide CDMO services. It is a broad incumbent in the CDMO space with overlapping biologics CDMO ambitions and substantially larger scale than Healsun.
• Hangzhou Tigermed: Hangzhou Tigermed is one of China's largest clinical CROs that has expanded into biopharmaceutical CDMO and laboratory services. Comparable as a Chinese-based biopharma services provider but with a much broader portfolio spanning clinical trials, biologics CDMO, and lab services.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healsun Biopharm